AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04164758 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Quetiapine
Description: Quetiapine 25 mg (provided as 1×25 mg quetiapine encapsulated tablet and 1 × placebo encapsulated tablet), OR 50 mg (provided as 2×25 mg quetiapine encapsulated tablets), OR 100 mg (provided as 2×50 mg quetiapine encapsulated tablets) administered orally as a single dose once daily
Study NCT03869424 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active Placebo labelled as antidepessant
Description: Participants receive an active nasal spray that is in fact a placebo.
Study NCT05475431 — intervention group
Intervention type: DRUG
Intervention: The sequential therapy
Description: Proton pump inhibitors and amoxicillin for the first 5 or 7 days and sequent proton pump inhibitors, clarithromycin, and metronidazole for the next 5 or 7 days
Study NCT05475431 — intervention group
Intervention type: DRUG
Intervention: The triple therapy
Description: Proton pump inhibitors, amoxicillin, and clarithromycin for 7, 10, or 14 days.
Study NCT05475431 — intervention group
Intervention type: DRUG
Intervention: The hybrid therapy
Description: Proton pump inhibitors and amoxicillin starting from the 1st day and for a total of 10 or 14 days, and clarithromycin, and metronidazole starting from the 8th day and for a total of 7 days .
Study NCT05475431 — intervention group
Intervention type: DRUG
Intervention: The concomitant therapy
Description: Proton pump inhibitors, amoxicillin, clarithromycin, and metronidazole for a total of 7 or 14 days
Study NCT05475431 — intervention group
Intervention type: DRUG
Intervention: Bismuth-based quadruple therapy
Description: Proton pump inhibitors, bismuth, tetracycline, and metronidazole for a total of 10 or 14 days
Study NCT03788044 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education
Description: Education + Medication adherence monitoring + Feedback when low adherence
Study NCT03253627 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Enhancement Program
Description: The HEP control, which was developed to serve as an active control to MBSR, will receive manualized health education from experts in physical activity, functional movement, music therapy, and nutrition-without mindfulness instruction-using similar modalities to MBSR training for a matched schedule.
Study NCT04432207 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMU-201 (administered as PD1-Vaxx) - Regimen 1
Description: IMU-201 consists of APi2568 (lyophilized IMU-201) dissolved in WFI and emulsified with the adjuvant (Montanide ISA 720 VG) to produce PD1-Vaxx. IMU-201 will be administered as PD1-Vaxx intramuscularly into the deltoid region of the upper arm on Days 1, 15, 29, 64 and thereafter every 63 days until discontinuation from study.
Study NCT03253627 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction
Description: The MBSR group will receive training from a certified instructor during a group-based, 2.5-hour manualized educational activity weekly for eight weeks. Activities include body scans, gentle stretching, yoga, and mindful awareness. Participants will be asked to complete daily 45-minute, audio-guided mindfulness activities and a one-day weekend retreat to reinforce learning.
Study NCT03079778 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: transarterial chemoembolization
Description: Transcatheter arterial chemoembolization (also called transarterial chemoembolization or TACE) is a minimally invasive procedure performed in interventional radiology to restrict a tumor's blood supply
Study NCT03079778 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: transarterial chemoembolization
Description: Transcatheter arterial chemoembolization (also called transarterial chemoembolization or TACE) is a minimally invasive procedure performed in interventional radiology to restrict a tumor's blood supply
Study NCT03079778 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: TACE plus RT
Description: radiobiologically guided radiation
Study NCT01303328 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: C1
Description: Local application of the experimental gel or placebo gel.
Study NCT01303328 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C1
Description: Local application of the experimental gel or placebo gel.
Study NCT04595331 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sculptra Aethestic reconsituted with 8ml Sterile Water for Injection
Description: Sculptra Aesthetic 8ml and Lidocaine treatment of cheek wrinkles
Study NCT02919371 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Description: Oral therapy ( Anti-vascular endothelial growth factor Tyrosin Kinase Inhibitor): given as 50 mg daily from day 1 to day 28- cycle repeated every 42 days
Study NCT02919371 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Monoclonal antibody against vascular endothelial growth factor: given intravenously on day 29 of each sunitinib cycle
Study NCT02563977 — intervention group
Intervention type: DEVICE
Intervention: 2 year postop CT scan of the abdomen
Description: CT scan of the abdomen (from the xiphoid process to the symphysis) performed approximately two years after performed DIEP flap breast reconstruction. No contrast used. Low dose of radiation.
Study NCT01180374 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Delta-9-THC
Description: Active Delta-9-THC (0.035mg/Kg) given intravenously over 20 minutes. The dose of THC that you may receive is a small dose and is roughly equivalent to smoking approximately one half to one whole marijuana cigarette, or joint.
Study NCT02786329 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TIVA+lidocaine
Description: Patients will be subjected to total intravenous anesthesia with propofol-fentanyl+i.v. lidocaine infusion for the first 48 h postoperatively
Study NCT02786329 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane+lidocaine
Description: Patients will be subjected to anesthesia with sevoflurane- fentanyl + lidocaine infusion for the first 48 h postoperatively.
Study NCT02786329 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TIVA+placebo
Description: Patients will be subjected to TIVA with propofol-fentanyl + saline infusion for the first 48 h postoperatively
Study NCT02786329 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sevoflurane+placebo
Description: Patients will be subjected to anesthesia with sevoflurane-fentanyl + saline infusion for the first 48 h postoperatively
Study NCT01840072 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active antihypertensive treatment
Description: Initial antihypertensive treatment with angiotensin-converting enzyme inhibitors (Enalapril) and/or calcium channel blockers as second line medication; and/or diuretics as third line medications. Based on patients' baseline BP level, the first-line medication (intravenous Enalapril) can be used alone, or in combination with second-line medication (calcium channel blocker), and third-line medication (diuretics) to achieve the target systolic BP lowering by 10% to 25% within the first 24 hours after randomization and to achieve systolic BP below 140 mm Hg and diastolic BP below 90 mm Hg and maintain this BP level afterwards during the hospitalization.
Study NCT02487329 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Calcium Hydroxide
Description: Exposed area was sealed with a self-hardening calcium hydroxide paste then final restoration was completed using a resin-modified glass ionomer and a nanohybrid composite resin
Study NCT00195273 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sirolimus
Description: 15 mg loading dose, followed by 5 mg/day to achieve target trough levels of 10-15 ng/mL at months 1-6, then 8-12 ng/mL at months 7-12
Study NCT00195273 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclosporine
Description: Initial dose of 10 mg/kg/day, then twice daily to achieve target trough levels of 300-400 ng/mL at weeks 0-4; 200-300 ng/mL at months 1-2; 150-250 ng/mL at months 2-3; 100-200 ng/mL at months 3-6; 75-150 ng/mL months 6-12
Study NCT02487329 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Er,Cr:YSGG laser + calcium hydroxide
Description: After the exposed area was irradiated with Er,Cr:YSGG laser at an energy level of 0,5 W, a repetition rate of 20 Hz, 140 µs pulse duration with 0% water and 45% air for 10 s, it was sealed with a self-hardening calcium hydroxide paste.Then final restoration was completed using a resin-modified glass ionomer and a nanohybrid composite resin
Study NCT02487329 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TheraCal LC
Description: TheraCal LC was applied directly to the exposed pulp with a needle tip syringe in incremental layers that was not to exceed 1 mm in depth. Then final restoration was completed using a resin-modified glass ionomer and a nanohybrid composite resin
Study NCT02487329 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Er,Cr:YSGG laser + TheraCal LC
Description: After the exposed area was irradiated with Er,Cr:YSGG laser at an energy level of 0,5 W, a repetition rate of 20 Hz, 140 µs pulse duration with 0% water and 45% air for 10 s, TheraCal LC was used to seal the treated area. Then final restoration was completed using a resin-modified glass ionomer and a nanohybrid composite resin
Study NCT02260232 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise training
Study NCT01180374 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Delta-9-THC
Description: Active Delta-9-THC (0.035mg/Kg) given intravenously over 20 minutes. The dose of THC that you may receive is a small dose and is roughly equivalent to smoking approximately one half to one whole marijuana cigarette, or joint.
Study NCT00195273 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil
Description: 1 g twice daily; may be reduced to 750 mg BID for adverse events, or to 500 mg BID for persisting adverse events
Study NCT00195273 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mycophenolate mofetil
Description: 1 g twice daily; may be reduced to 750 mg BID for adverse events, or to 500 mg BID for persisting adverse events
Study NCT00195273 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: corticosteroids
Description: As per center practice. By day 8 prednisolone tapered to 20 mg/day; by day 30 to 15 mg/day; by day 60 to 10 mg/day; after 4 to 6 months to 5-7.5 mg/day
Study NCT00195273 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: corticosteroids
Description: As per center practice. By day 8 prednisolone tapered to 20 mg/day; by day 30 to 15 mg/day; by day 60 to 10 mg/day; after 4 to 6 months to 5-7.5 mg/day
Study NCT02199912 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy of adipose and muscular tissue
Study NCT00195273 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: daclizumab
Description: IV: 1 mg/kg to a maximum of 100 mg/dose. 5 doses at 2, 4, 6, and 8 weeks after transplantation
Study NCT02199912 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood sampling
Study NCT02199912 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Calorimetry
Study NCT02910362 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Alcon phacoemulsification equipment
Description: cataract surgery with Alcon phacoemulsification equipment.
Study NCT02199912 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Impedance measure
Description: Evaluation of physical composition (non-invasive method)
Study NCT02199912 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Evaluation of nutritional status
Description: Nutritional status will be assessed by using the Mini Nutritional Assessment (MNA) questionnaire and a scale that evaluates anorexia
Study NCT02199912 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Evaluation of physical performance
Description: This will be assessed by using a tiredness scale named Echelle Visuelle Analogique (EVA) in french
Study NCT02199912 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Evaluation of muscular strength
Description: Muscular strength will be assessed thanks to the Handgrip Strength Test and the Short Physical Performance Battery (SPPB)
Study NCT02199912 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Evaluation of emotional status
Description: The emotional status wil be assessed thanks to the Yesavage Geriatric Depression Scale (GDS)
Study NCT02199912 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Evaluation of functional status
Description: The functional status will be assessed by using the Activity of Daily Life (ADL) questionnaire and the Instrumental Activities of Daily Living (IADL) Questionnaire
Study NCT02910362 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AMO phacoemulsification equipment
Description: cataract surgery with AMO phacoemulsification equipment.
Study NCT02116231 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Concurrent chemotherapy with cisplatin
Description: Three cycles of weekly Cisplatin 100 mg/m2 starting on the first day of IMRT
Study NCT02116231 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity modulated radiotherapy
Description: Intensity modulated radiotherapy is a technique of radiotherapy.
Study NCT02116231 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Intensity modulated radiotherapy
Description: Intensity modulated radiotherapy is a technique of radiotherapy.
Study NCT05059171 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: OneSahpe single file
Description: The rotary motion of OneShape single file
Study NCT05059171 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: WaveOne Gold single file
Description: reciprocation motions of WaveOne Gold single file
Study NCT03025841 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Ceftaroline
Study NCT00962338 — intervention group
Intervention type: BEHAVIORAL
Intervention: Information
Description: Information on short convalescence (1 day). Example: Operated today and getting started with normal activities again tomorrow.
Study NCT01871922 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline
Study NCT01871922 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atropine
Description: Atropine
Study NCT04011241 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1323495
Description: Tablet
Study NCT04011241 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Oral solution
Study NCT03653819 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: First exercise session + compression
Description: The Interval Training consists of a 5 minute warm-up on the stationary bike followed by 7 intervals of cycling for 1 minute at level 15-16 on the Borg Scale of Perceived Exertion. Inbetween intervals, participants reduce resistance on the stationary bike and pedals for 1 minute at level 11-12 on the Borg Scale. The session ends with a 5-10 minute cool-down pedaling and stretching exercises for the lower limbs.
Study NCT03653819 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: First exercise session - compression
Description: The Interval Training consists of a 5 minute warm-up on the stationary bike followed by 7 intervals of cycling for 1 minute at level 15-16 on the Borg Scale of Perceived Exertion. Inbetween intervals, participants reduce resistance on the stationary bike and pedals for 1 minute at level 11-12 on the Borg Scale. The session ends with a 5-10 minute cool-down pedaling and stretching exercises for the lower limbs.
Study NCT04432207 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMU-201 (administered as PD1-Vaxx) - Regimen 2
Description: IMU-201 consists of APi2568 (lyophilized IMU-201) dissolved in WFI and emulsified with the adjuvant (Montanide ISA 720 VG) to produce PD1-Vaxx. IMU-201 will be administered as PD1-Vaxx intramuscularly into the deltoid region of the upper arm on Days 1, 15, 29, 57 and thereafter every subsequent 63 days until discontinuation from study.
Study NCT01256047 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Oral IMPACT
Description: oral supplement for 5 days(1L/day) before surgery of a formula enriched with arginine, omega-3 fatty acids, and RNA
Study NCT05781685 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Testosterone
Description: Sublingual testosterone was administered to participants. Participants would self-administer the testosterone to themselves.
Study NCT05781685 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone
Description: Sublingual testosterone was administered to participants. Participants would self-administer the testosterone to themselves.
Study NCT05781685 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Syrup
Description: Oil-based sublingual product.
Study NCT05781685 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo Syrup
Description: Oil-based sublingual product.
Study NCT04005326 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quadratus lumborum block; (Anterior QLB or QLB III)
Description: The patient will be in the lateral position. A low frequency convex probe will be vertically attached above the iliac crest and a needle will be inserted in plane from the posterior edge of the convex probe through the quadratus lumborum in an anteromedial direction. The needle tip will be placed between the psoas major muscle and the quadratus lumborum muscle. After negative aspiration, 30 mL of 0.25 % of bupivacaine will be injected into the fascial plane incrementally, aspirating every 5 ml.
Study NCT04005326 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: suprainguinal fascia iliaca block
Description: In supine position, a high frequency linear probe will be placed in the inguinal crease. Scan starting laterally from the femoral artery and nerve in inguinal crease to identify the sartorius muscle, tracing the muscle until it's origin to anterior superior iliac spine. The shadow of the bony of iliac crest \& iliacus muscle will be seen, the end point of the injection is deep to the fascia iliaca and above the iliacus muscle in the lateral part of the iliacus muscle. After negative aspiration, 30 mL of 0.25 % of bupivacaine will be injected under the fascial plane incrementally, aspirating every 5 ml.
Study NCT04005326 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Subarachnoid block
Description: Patients will receive SAB using 25g spinal needle in the lateral position. Fifteen milligrams of hyperbaric bupivacaine will be administered at L3-L4 or at L4-L5 interspace in addition to 25 mcg fentanyl with rapid crystalloid co-load.~Spinal anesthesia will be considered successful when a bilateral block to T12, as assessed by loss of cold (cold ice) and pain (a 23-gauge needle) sensations, will be established 10 -minutes after the intrathecal injection. If spinal anesthesia failed, such patients will be administered general anesthesia and will be excluded from this study.
Study NCT00831883 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Partner-Specific IMB-based HIV risk reduction intervention
Description: 5 session partner-specific HIV risk reduction group intervention based on the Information-Motivation-Behavioral Skills model.
Study NCT00831883 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Healthy Lifestyle
Description: 5 session psychoeducational group, designed to provide equivalent time and attention, that focuses on the importance of maintaining a good diet, exercise, and developing health skills.
Study NCT00666042 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vigamox - administration in spray form
Description: Vigamox will be administered in a spray form
Study NCT00666042 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vigamox eye drops
Description: Vigamox eye drops
Study NCT06322901 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Flap
Description: Different flap designs for implant placement
Study NCT06322901 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Flap
Description: Different flap designs for implant placement
Study NCT02071732 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: real repetitive Transcranial Magnetic Stimulation
Study NCT02071732 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham repetitive Transcranial Magnetic Stimulation
Description: This sham stimulation is not true stimulation.
Study NCT04432207 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMU-201 (administered as PD1-Vaxx) - Regimen 3
Description: IMU-201 consists of APi2568 (lyophilized IMU-201) dissolved in WFI and emulsified with the adjuvant (Montanide ISA 720 VG) to produce PD1-Vaxx. IMU-201 will be administered as PD1-Vaxx intramuscularly into the deltoid region of the upper arm on Days 1, 15, 29, 57 and thereafter every 56 or 63 days until discontinuation from study.
Study NCT00437073 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: capecitabine 2000mg/m2/day orally, Days 1-14, every 21 days
Study NCT04432207 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be administered every 2 weeks (Q2W) starting Day 15 until discontinuation from study.
Study NCT00437073 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: topotecan
Description: topotecan intravenous (IV, in the vien) 3.2mg/m2 Days 1, 8 and 15; every 28 days
Study NCT00437073 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lapatinib
Description: lapatinib administered 1250mg once daily orally
Study NCT04652297 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS-10356
Description: Single dose of HS-10356